Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

Acute lymphoblastic leukemia (ALL) is a fast-growing leukemia ... Researchers have observed that the long-term survival rate for children with ALL is nearly 90%. A 2021 study looked at survival ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

Kansas children battling leukemia have a new hope for survival thanks to a new treatment available in Wichita. KU School of ...

Seven-year-old WA boy Ace was diagnosed with Acute Lymphoblastic Leukemia when he was just five years old. Acute lymphoblastic leukemia (ALL) is a type of blood cancer that occurs when the bone marrow ...

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's ...

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. In this phase 3, open-label trial, we included ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

For patients with an average risk of relapse from acute lymphoblastic leukemia, survival rates rose to 97.5% with the new drug regimen vs. 90.2% for those without blinatumomab. For high-risk ...